Gameto Secures $33M in Series B Funding to Transform Fertility Treatments
June 6, 2024, 9:33 am
In a bold move that is set to revolutionize the fertility market, Gameto, a cutting-edge biotechnology company headquartered in New York City, has successfully raised $33 million in Series B funding. This significant investment, spearheaded by Two Sigma Ventures and RA Capital, marks a pivotal moment for Gameto as they continue to push the boundaries of women's health with their innovative approach to fertility treatments.
Gameto's flagship product, Fertilo, is a game-changer in the field of reproductive medicine. By harnessing the power of cell engineering, Fertilo offers a novel in vitro maturation solution that promises to streamline the IVF and egg freezing process, making it faster, safer, and more accessible than ever before. With a focus on reducing the need for injections and shortening the timeline for fertility treatments to just 2-3 days, Fertilo has the potential to transform the lives of millions of individuals struggling with infertility.
The fertility market in the United States alone is estimated to be worth over $8 billion, yet only a small fraction of newborns are conceived through IVF. The prohibitive costs, intensive nature, and discomfort associated with traditional fertility treatments have long been barriers to wider adoption. Gameto's innovative approach aims to address these challenges head-on, offering hope to those facing fertility issues and paving the way for a more inclusive and accessible reproductive healthcare landscape.
Dr. Dina Radenkovic, CEO and Co-founder of Gameto, is at the helm of this groundbreaking initiative. With a background in women's health and a passion for improving treatment options in this underserved space, Dr. Radenkovic and her team are dedicated to pushing the boundaries of what is possible in reproductive medicine. Through their collaboration with leading investors and industry experts, Gameto is poised to make a lasting impact on the field of fertility treatments.
The recent Series B funding round, which brings Gameto's total funds raised to $73 million, has attracted a diverse group of investors, including Insight Partners, Future Ventures, and BOLD Capital Partners. New investors such as Olivia Walton's Ingeborg Investments, AmplifyHER Ventures, Stacey Bendet Eisner of alice + olivia, and Chelsea Hirschhorn of Frida have also joined the ranks of supporters, recognizing the immense potential of Gameto's innovative approach to women's health.
Looking ahead, Gameto is focused on advancing the clinical development of Fertilo and preparing for commercial launches in Australia and Latin America, where the product is already making waves in the clinic. With a commitment to scientific rigor, innovation, and patient-centered care, Gameto is poised to lead the way in transforming the landscape of fertility treatments and offering new hope to individuals struggling with reproductive health challenges.
Gameto's flagship product, Fertilo, is a game-changer in the field of reproductive medicine. By harnessing the power of cell engineering, Fertilo offers a novel in vitro maturation solution that promises to streamline the IVF and egg freezing process, making it faster, safer, and more accessible than ever before. With a focus on reducing the need for injections and shortening the timeline for fertility treatments to just 2-3 days, Fertilo has the potential to transform the lives of millions of individuals struggling with infertility.
The fertility market in the United States alone is estimated to be worth over $8 billion, yet only a small fraction of newborns are conceived through IVF. The prohibitive costs, intensive nature, and discomfort associated with traditional fertility treatments have long been barriers to wider adoption. Gameto's innovative approach aims to address these challenges head-on, offering hope to those facing fertility issues and paving the way for a more inclusive and accessible reproductive healthcare landscape.
Dr. Dina Radenkovic, CEO and Co-founder of Gameto, is at the helm of this groundbreaking initiative. With a background in women's health and a passion for improving treatment options in this underserved space, Dr. Radenkovic and her team are dedicated to pushing the boundaries of what is possible in reproductive medicine. Through their collaboration with leading investors and industry experts, Gameto is poised to make a lasting impact on the field of fertility treatments.
The recent Series B funding round, which brings Gameto's total funds raised to $73 million, has attracted a diverse group of investors, including Insight Partners, Future Ventures, and BOLD Capital Partners. New investors such as Olivia Walton's Ingeborg Investments, AmplifyHER Ventures, Stacey Bendet Eisner of alice + olivia, and Chelsea Hirschhorn of Frida have also joined the ranks of supporters, recognizing the immense potential of Gameto's innovative approach to women's health.
Looking ahead, Gameto is focused on advancing the clinical development of Fertilo and preparing for commercial launches in Australia and Latin America, where the product is already making waves in the clinic. With a commitment to scientific rigor, innovation, and patient-centered care, Gameto is poised to lead the way in transforming the landscape of fertility treatments and offering new hope to individuals struggling with reproductive health challenges.